Industry News
Union Budget 2026–27: Strengthening India’s Biopharma Ecosystem and Healthcare Access
HRV Pharma CEO Hari Kiran Chereddi shares his insights on how Union Budget 2026–27’s focus on biopharma innovation, affordable cancer care, and healthcare infrastructure will shape India’s pharmaceutical future.
How Virtual Manufacturing Is Solving Structural Causes of Global Drug Shortages
Virtual pharmaceutical manufacturing models are helping solve structural drug shortages by connecting global GMP capacity, improving supply flexibility, and strengthening regulatory execution.
HRV Pharma Partners with Haleos Labs to Accelerate Orphan and Niche API Development
HRV Pharma has entered a multi‑year strategic partnership with Haleos Labs to accelerate the development and manufacture of orphan and niche APIs, strengthening global access to complex therapies for rare diseases.
How HRV Pharma’s Virtual Model Helps Solve America’s Drug Shortage Crisis
HRV Pharma’s capital‑efficient virtual pharmaceutical model is helping address America’s drug shortage crisis by linking underutilized global manufacturing capacity with regulatory strength to ensure consistent API supply.
HRV Pharma Redefines India’s Bulk Drug Business with a Virtual Pharma Model
Fortune India features HRV Pharma for pioneering a capital‑efficient virtual pharma model that is transforming India’s bulk drug and API ecosystem through speed, compliance, and global regulatory execution.
Indian Biosimilars on the Global Stage: HRV Pharma CEO's Insights in Express Pharma
India's rise in biosimilars & biologics. Full clipping + insights included.
Pharma Safety, ESG and Virtual Manufacturing: Insights from Hari Kiran Chereddi
Workplace safety in pharma can no longer be a checklist exercise. This blog shares how HRV Pharma, led by MD & CEO Hari Kiran Chereddi, is using virtual manufacturing networks, stronger EHS governance, and ESG‑aligned practices to raise safety standards across partner sites and protect people, reputation, and India’s role as the world’s pharmacy.
GLP-1 Patents Are Fading - Can India Become the GLP-1 Generics Powerhouse
As GLP-1 patents expire, India’s manufacturing scale, peptide chemistry expertise, and compliance readiness could position it to supply affordable GLP-1 generics globally — but consistency and supply reliability will decide who wins
AI Is Redefining Pharma Forecasting and Eliminating the Compliance Trade-Off
Pharmaceutical Commerce features HRV Pharma on how AI-validated digital backbones speed regulatory reviews, improve supplier onboarding, and make forecasting more reliable.
From Pharmacy to Intelligent Pharmacy: AI's Role in India's Pharma Evolution
HRV Pharma's CEO Hari Kiran Chereddi discusses how AI is transforming India from the traditional "pharmacy of the world" into the "intelligent pharmacy of the world," revolutionizing drug discovery, regulatory processes, and supply chain management
Cheaper Obesity Drugs: Cure or Crisis for India?
HRV Pharma's CEO examines the implications of cheaper GLP-1 obesity drugs coming to India post-semaglutide patent expiry, highlighting both transformative potential and misuse risks requiring careful regulation.
From Volume to Value: India's Strategic API Leadership Evolution
HRV Global's Managing Director Hari Kiran Chereddi discusses India's transformation from volume-driven API supplier to value-oriented strategic partner, highlighting virtual pharma models and AI-driven operations.
US Tariffs Threaten Indian Pharma Exports-Urgent Need for Diversification and Policy Support
Our leadership analyzes impact of US 50% tariffs on Indian pharmaceutical exports, highlighting challenges for SMEs and strategic responses including market diversification.
India's Pharma Industry Goes Global: From Generics to Innovation Leadership
HRV Pharma's CEO Hari Kiran Chereddi analyzes India's pharmaceutical transformation from affordable generics manufacturer to global hub of compliance, innovation, and supply chain excellence.
GLP-1 Patent Expiry 2026: A Defining Opportunity for Indian Pharma
HRV Pharma's CEO Hari Kiran Chereddi analyzes India's strategic opportunity in GLP-1 drug manufacturing as Semaglutide patents expire in 2026, emphasizing the shift from reverse engineering to innovative design.
The US Drug Pricing Shock: A Mandate for Recalibration, Not Reaction
HRV Pharma's CEO Hari Kiran Chereddi outlines strategic recalibration approach to US drug pricing policies, emphasizing global diversification and value-based transformation over reactive market responses.
Express Pharma June 2025 Feature : The New Rules of Pharma
HRV Pharma is redefining pharmaceutical manufacturing through distributed orchestration, compliance-driven models, and technology-first strategies to build resilient, globally connected supply chains for the future.
Trump's MFN Executive Order Strengthens Generic and Biosimilar Adoption
Analysis of President Trump's Most Favored Nation executive order impact on generic and biosimilar markets, with HRV Pharma's strategic insights on opportunities for Indian pharmaceutical manufacturers
Lifesciences Sector Maximizes Adoption of Advanced Technologies to Unlock New Possibilities
HRV Pharma is reshaping pharmaceutical manufacturing through compliance-first strategies, distributed orchestration, and technology-driven innovation, as featured in Express Pharma’s June 2025 edition.
Market Momentum: Dynamic Drivers of Pharmaceutical Growth
Comprehensive analysis of key forces driving pharmaceutical industry transformation, from biotech advances and AI-powered drug discovery to emerging markets and virtual pharma models reshaping global healthcare.
Pharma 4.0: Smart Manufacturing Redefining Generic Drug Production
Explore how AI, automation, and real-time analytics are transforming generic drug production through smart manufacturing and continuous processes.
India's Strategic Role in the Global Medtech Reset: Navigating US Tariffs
Our CEO Hari Kiran Chereddi shares insights in Citeline Medtech Insight on India's role in global supply chains amidst US medical device tariffs.
US Tariff Relief for Indian Pharma: A Strategic Opportunity for Growth?
Discover how Indian pharma can leverage US tariff relief to strengthen partnerships, innovate, and maintain global competitiveness in healthcare affordability.
India's API Industry at a Key Juncture: Navigating Global Supply Chain Dynamics
HRV Pharma's Sreenivas Varma discusses India's API industry transformation, PLI schemes, and the shift towards high-value pharmaceutical manufacturing.
US Tariffs: An Opportunity for Indian Pharma to Reinvent Itself
The possibility of increased US tariffs has sparked concerns within the Indian pharmaceutical sector. However, instead of viewing this as a setback, it's time to consider it a catalyst for strategic reinvention and growth.
How Indian Pharma is Preparing to Mitigate US Tariff Challenges
HRV Pharma's leadership discusses strategic approaches for Indian pharmaceutical companies to navigate potential US tariff challenges while maintaining global competitiveness and healthcare affordability.
Pharma Leveraging AI: Transforming the Future of Drug Development
The pharmaceutical industry is undergoing a revolution, powered by Artificial Intelligence (AI). As highlighted in a recent article, AI is transforming drug discovery, clinical trials, disease diagnosis, and manufacturing processes.
Indian Pharma's Strategic US Expansion: Insights from Hari Kiran Chereddi
Hari Kiran Chereddi shares strategic insights on Indian pharma’s US expansion via acquisitions, regulatory agility, and supply chain resilience in a competitive market.
HRV Pharma Showcases Virtual Manufacturing Innovation at Industry Conference
CEO Hari Kiran Chereddi highlights HRV’s virtual manufacturing model, blending AI and blockchain to redefine pharma production and global market access.
HRV Pharma Eyes Strategic Expansion into Sri Lankan Pharmaceutical Market
HRV Pharma has announced its strategic interest in expanding operations into Sri Lanka, positioning the island nation as a key growth market in the company's South Asian expansion strategy.
Hari Kiran Chereddi Featured in Exclusive CPhI Milan Interview
HRV’s CEO discusses virtual pharma models and navigating complex global markets in a CPhI Milan interview, emphasizing innovation and regulatory mastery.
CNN Business Arabic has featured HRV Global Life Sciences
CNN Business Arabic highlights HRV Global's resilient supply chain strategies and ambitious Middle East expansion plans, showcasing success in complex markets including Iran, Iraq, and UAE.
HRV Pharma Honored with Dual Leadership Awards for Excellence in India and Middle East Markets
HRV Pharma has been honored with two prestigious leadership awards, recognizing the company as a leading pharmaceutical enterprise in both India and the Middle East markets